Antibody-PROTAC Conjugate Enables Selective Degradation of Receptor-Interacting Serine/Threonine-Protein Kinase 2 (RIPK2) in HER+ Cell Lines (2023)
Attributed to:
Accelerated Discovery and Development of New Medicines: Prosperity Partnership for a Healthier Nation
funded by
EPSRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.26434/chemrxiv-2023-97zdb
Publication URI: http://dx.doi.org/10.26434/chemrxiv-2023-97zdb
Type: Preprint